<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729911</url>
  </required_header>
  <id_info>
    <org_study_id>AATAC-AF</org_study_id>
    <nct_id>NCT00729911</nct_id>
  </id_info>
  <brief_title>Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD</brief_title>
  <official_title>Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Cardiac Arrhythmia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Casa Sollievo della Sofferenza IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southlake Regional Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Foggia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sutter Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Cardiac Arrhythmia Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To determine if catheter-based atrial fibrillation (AF) ablation is superior to
           Amiodarone treatment for symptomatic persistent/permanent AF in ICD/CRTD patients with
           an impaired left ventricular function.

        2. Hypothesis: AF ablation is better than Amiodarone for subjects with symptomatic
           persistent or permanent AF and impaired LV function in terms of recurrence of AF,
           quality of life, 6-minute walk distance, EF and total number of hospitalizations.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Recurrence of AF lasting longer than 15 seconds</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in distance walked in 6-minute walk test</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hospitalizations during the trial period for each group</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MLHF Quality of Life during trial period</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EF during trial period</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>AF ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.
Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amiodarone is taken orally on a daily basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial Fibrillation ablation</intervention_name>
    <description>Radio-frequency catheter ablation of atrial fibrillation</description>
    <arm_group_label>AF ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Taken orally on a daily basis.</description>
    <arm_group_label>Amiodarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with an dual chamber ICD or CRTD (with an existing functional atrial lead)
             with remote monitoring capabilities and EF &lt;= 40% within the last 3 months by
             echocardiogram, nuclear imaging, MRI or cardiac catheterization,

          2. Persistent or chronic symptomatic AF resistant to anti-arrhythmic medication other
             than Amiodarone. Resistant defined as recurrent AF of greater than 5 minutes duration
             at least once per month.

          3. Therapeutic anticoagulation for at least three weeks prior to initiation of therapy

          4. Ability to complete 6 minute walk test.

          5. Age &gt;= 18 years old. (Females must be either post-menopausal &gt;12 months, practicing a
             protocol-acceptable method of birth control [defined as injectable or implantable
             hormonal contraceptives, oral contraceptives, intrauterine device, diaphragm plus
             spermicide], or have had a hysterectomy, bilateral oophorectomy, or tubal ligation
             performed at least 6 months prior to enrollment).

          6. All patients optimized on CHF medications including beta-blocker and ace-inhibitor or
             angiotensin-receptor blocker.

          7. patients receiving low dose amiodarone- &lt;200 mg for 2 or less months

        Exclusion Criteria:

        The exclusion criteria are:

          1. Reversible causes of AF such as pericarditis, hyperthyroidism,

          2. Presently with Valvular Heart disease requiring surgical intervention

          3. Presently with coronary artery disease requiring surgical intervention

          4. Early Post-operative AF (within three months of surgery)

          5. Previous MAZE or left atrial instrumentation

          6. Prolonged QT interval

          7. Hypothyroidism

          8. Liver Failure

          9. Life expectancy &lt;= 2 years

         10. Social factors that would preclude follow up or make compliance difficult.

         11. Contraindication to the use of anti-arrhythmic medications and/or coumadin and heparin

         12. Enrollment in another investigational drug or device study.

         13. Patients with severe pulmonary disease i.e. COPD or asthma

         14. Documented intra-atrial thrombus, tumor, or another abnormality which precludes
             catheter introduction

         15. Any ophthalmologic disorders (other than requiring glasses for vision correction)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Di Biase, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Cardiac Arrhythmia Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Cardiac Arrhythmia Research Foundation</investigator_affiliation>
    <investigator_full_name>Andrea Natale</investigator_full_name>
    <investigator_title>Executive Medical Director</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

